(Total Views: 426)
Posted On: 11/20/2019 9:43:57 PM
Post# of 154734
I agree ohm. However, unless they plan to keep cancer or NASH, this is the best option IMO (although it puts a clock on shareholder value). They don’t (currently) have the expertise to build a research team, acquire early stage drug candidates, commercialize products etc.
If they keep cancer or NASH that would tell me they intend to build these teams, but at this point I think they are focused on the 5 meter targets and not shooting at the 300 meter targets until they get a few closer targets knocked down.
If they keep cancer or NASH that would tell me they intend to build these teams, but at this point I think they are focused on the 5 meter targets and not shooting at the 300 meter targets until they get a few closer targets knocked down.
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
